Endothelin receptor expression in idiopathic pulmonary arterial hypertension: Effect of bosentan and epoprostenol treatment

European Respiratory Journal

Volumn 38, Issue 4, 2011, Pages 851-860

  Hall, S M ^a   Davie, N ^c   Klein, N ^a   Haworth, S G ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Endothelin receptor A and B; Endothelin receptor antagonists; Endothelium; Paediatric idiopathic pulmonary arterial hypertension; Peripheral pulmonary arteries

Indexed keywords

BOSENTAN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR A; ENDOTHELIN RECEPTOR B; NIFEDIPINE; PROSTACYCLIN; SILDENAFIL; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION; IMMUNOHISTOCHEMISTRY; LUNG HEMODYNAMICS; LUNG PARENCHYMA; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; QUANTITATIVE ANALYSIS; SCHOOL CHILD;

ADOLESCENT; ANTIHYPERTENSIVE AGENTS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MUSCLE, SMOOTH, VASCULAR; NIFEDIPINE; NITRIC OXIDE SYNTHASE TYPE III; PIPERAZINES; PULMONARY ARTERY; PURINES; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; SULFONAMIDES; SULFONES; VASODILATOR AGENTS;

EID: 80053532227     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00167010     Document Type: Article

References (46)

1. Rosenzweig EB, Widlitz AC, Barst RJ, et al. Pulmonary arterial hypertension in children. Pediatr Pulmonol 2004; 38: 2-22. (Pubitemid 38823753)
2. Penna C, Rastaldo R, Mancardi D, et al. Effect of endothelins on the cardiovascular system. J CardiovascMed (Hagerstown) 2006; 7: 645-652. (Pubitemid 44319068)
3. Allen SW, Chatfield BA, Koppenhafer SA, et al. Circulating immunoreactive endothelin-1 in children with pulmonary hypertension. Association with acute hypoxic pulmonary vasoreactivity. Am Rev Respir Dis 1993; 148: 519-522. (Pubitemid 23221605)
4. Davie NJ, Schermuly RT, Weissmann N, et al. The science of endothelin-1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies. Eur J Clin Invest 2009; 39: 38-49.
5. Dewachter L, Adnot S, Fadel E, et al. Angiopoietin/Tie2 pathway influences smooth muscle hyperplasia in idiopathic pulmonary hypertension. Am J Respir Crit Care Med 2006; 174: 1025-1033. (Pubitemid 44684452)
6. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-1739. (Pubitemid 23170122)
7. Davenport AP, Kuc RE, Maguire JJ, et al. ET-A receptors predominate in the human vasculature and mediate constriction. J Cardiovasc Pharmacol 1995; 26: S265-S267.
8. Liu S, Premont RT, Kontos CD, et al. Endothelin-1 activates endothelial cell nitric oxide synthase via heterotrimeric G-protein bc subunit signaling to protein kinase B/Akt. J Biol Chem 2003; 278: 49929-49935. (Pubitemid 37548828)
9. Maguire JJ, Yu JC, Davenport AP. ET-A receptor antagonists inhibit intimal smooth muscle cell proliferation in human vessels. Clin Sci (Lond) 2002; 103: Suppl. 48, 184S-188S. (Pubitemid 35007148)
10. Tian J, Wong WT, Tian XY, et al. Rosiglitazone attenuates endothelin-1-induced vasoconstriction by upregulating endothelial expression of endothelin-B receptor. Hypertension 2010; 56: 129-135.
11. Kalk P, Mach A, Thone-Reineke C, et al. Pulmonary fibrosis in L-NAME-treated mice is dependent on an activated endothelin system. Can J Physiol Pharmacol 2008; 86: 541-545.
12. Hall S, Brogan P, Haworth SG, et al. Contribution of inflammation to the pathology of idiopathic pulmonary arterial hypertension in children. Thorax 2009; 64: 778-783.
13. Muller DN, Mervaala EM, Schmidt F, et al. Effect of bosentan on NF-κB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension 2000; 36: 282-290. (Pubitemid 30627001)
14. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: Suppl. 1, 13S-24S. (Pubitemid 38759713)
15. Langleben D, Orfanos SE, Giovinazzo M, et al. Pulmonary capillary endothelial metabolic dysfunction: severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension. Arthritis Rheum 2008; 58: 1156-1164. (Pubitemid 351564019)
16. Haworth SG, Hislop AA. Pulmonary vascular development: normal values of peripheral vascular structure. Am J Cardiol 1983; 52: 578-583. (Pubitemid 13049191)
17. Hislop AA, Moledina S, Foster H, et al. Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children. Eur Respir J 2011; 38: 70-77.
18. Breu V, Hashido K, Broger C, et al. Separable binding sites for the natural agonist endothelin-1 and the non-peptide antagonist bosentan on human endothelin-A receptors. Eur J Biochem 1995; 231: 266-270.
19. Kuc RE, Maguire JJ, Davenport AP. Quantification of endothelin receptor subtypes in peripheral tissues reveals downregulation of ET-A receptors in ET-B-deficient mice. Exp Biol Med (Maywood) 2006; 231: 741-745. (Pubitemid 43845520)
20. Avedanian L, Riopel J, Bkaily G, et al. ET-A receptors are present in human aortic vascular endothelial cells and modulate intracellular calcium. Can J Physiol Pharmacol 2010; 88: 817-829.
21. Hansen-Schwartz J, Szok D, Edvinsson L. Expression of ET-A and ET-B receptor mRNA in human cerebral arteries. Br J Neurosurg 2002; 16: 149-153. (Pubitemid 34539018)
22. Kuhlmann A, Amann K, Schlotzer-Schrehardt U, et al. Endothelin- 1 and ET-A/ET-B receptor protein and mRNA: expression in normal and vascularized human corneas. Cornea 2005; 24: 837-844. (Pubitemid 41400424)
23. Hoosein MM, Dashwood MR, Dawas K, et al. Altered endothelin receptor subtypes in colorectal cancer. Eur J Gastroenterol Hepatol 2007; 19: 775-782. (Pubitemid 47266706)
24. Carlini RG, Gupta A, Liapis H, et al. Endothelin-1 release by erythropoietin involves calcium signaling in endothelial cells. J Cardiovasc Pharmacol 1995; 26: 889-892.
25. McCarter SD, Lai PF, Suen RS, et al. Regulation of endothelin-1 by angiopoietin-1: implications for inflammation. Exp Biol Med (Maywood) 2006; 231: 985-991. (Pubitemid 43845564)
26. Baker SM, Kim N, Gumpert AM, et al. Acute internalization of gap junctions in vascular endothelial cells in response to inflammatory mediator-induced G-protein coupled receptor activation. FEBS Lett 2008; 582: 4039-4046.
27. Verri WA Jr, Cunha TM, Magro DA, et al. Targeting endothelin ET-A and ET-B receptors inhibits antigen-induced neutrophil migration and mechanical hypernociception in mice. Naunyn Schmiedebergs Arch Pharmacol 2009; 379: 271-279.
28. Gourine AV, Gonon AT, Pernow J. Involvement of nitric oxide in cardioprotective effect of endothelin receptor antagonist during ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2001; 280: H1105-H1112.
29. Kowala MC, Rose PM, Stein PD, et al. Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Am J Pathol 1995; 146: 819-826.
30. Bhalla A, Haque S, Taylor I, et al. Endothelin receptor antagonism and cancer. Eur J Clin Invest 2009; 39: 74-77.
31. Rosano L, Spinella F, Di C, et al. Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo. Am J Pathol 2003; 163: 753-762. (Pubitemid 36909436)
32. Rai PR, Cool CD, King JAC, et al. The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 178: 558-564.
33. Langleben D, Dupuis J, Langleben I, et al. Etiology-specific endothelin-1 clearance in human precapillary pulmonary hypertension. Chest 2006; 129: 689-695.
34. Friedman R, Mears JG, Barst RJ, et al. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997; 96: 2782-2784. (Pubitemid 27500070)
35. Davie N, Haleen SJ, Upton PD, et al. ET-A and ET-B receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002; 165: 398-405. (Pubitemid 34118516)
36. Abraham DJ, Vancheeswaran R, Dashwood MR, et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol 1997; 151: 831-841. (Pubitemid 27385615)
37. McCulloch KM, Docherty CC, Morecroft I, et al. Endothelin B receptor-mediated contraction in human pulmonary resistance arteries. Br J Pharmacol 1996; 119: 1125-1130. (Pubitemid 26385981)
38. Taurin S, Hogarth K, Sandbo N, et al. Gbc-mediated prostacyclin production and cAMP-dependent protein kinase activation by endothelin-1 promotes vascular smooth muscle cell hypertrophy through inhibition of glycogen synthase kinase-3. J Biol Chem 2007; 282: 19518-19525. (Pubitemid 47100116)
39. Prins BA, Hu RM, Nazario B, et al. Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. J Biol Chem 1994; 269: 11938-11944.
40. Wort SJ, Mitchell JA, Woods M, et al. The prostacyclin-mimetic cicaprost inhibits endogenous endothelin-1 release from human pulmonary artery smooth muscle cells. J Cardiovasc Pharmacol 2000; 36: Suppl. 1, S410-S413.
41. Langleben D, Barst RJ, Badesch D, et al. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. Circulation 1999; 99: 3266-3271. (Pubitemid 29293437)
42. Williamson DJ, Wallman LL, Jones R, et al. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation 2000; 102: 411-418. (Pubitemid 30490679)
43. Tuder RM, Cool CD, Yeager M, et al. The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med 2001; 22: 405-418.
44. Salani D, Taraboletti G, Rosano L, et al. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 2000; 157: 1703-1711.
45. Lalich M, McNeel DG, Wilding G, et al. Endothelin receptor antagonists in cancer therapy. Cancer Invest 2007; 25: 785-794. (Pubitemid 350223171)
46. Falcetti E, Hall SM, Phillips PG, et al. Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 182: 1161-1170.